LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article: Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.

García-Fraile, Lucio J / García-Buey, Luisa / Alonso Cerezo, Concepción / Sanz Sanz, Jesús / de Los Santos Gil, Ignacio

2021 Volume 45, Issue 4, Page(s) 249–255

Abstract: Objectives: Porphyria cutanea tarda (PCT) is common and usually associated with HCV chronic infection and HFE polymorphisms. Since DAA IFN-free regimens availability, SVR for HCV is nearly a constant and we wonder whether HCV SVR determine PCT evolution. ...

Abstract	Objectives: Porphyria cutanea tarda (PCT) is common and usually associated with HCV chronic infection and HFE polymorphisms. Since DAA IFN-free regimens availability, SVR for HCV is nearly a constant and we wonder whether HCV SVR determine PCT evolution. Methods: Retrospective observational study including patients with HCV associated PCT from the Gastroenterology and Infectious Diseases Departments at our Hospital, treated with DAA (Apr/2015-Apr/2017). Clinical variables of PCT were collected at PCT diagnosis, after PCT treatment, before DAA use and after SVR achievement. UROD activity and C282Y/H63D polymorphisms were registered. SPSS 22.0. Results: 13 HCV-PCT patients included: median age 52.5 years; 4 females; 8 HCV/HIV co-infected (all on undetectable viral load). Classical PCT factors: 12 smoked, 9 alcohol abuse, 6 former IDU. 10 type I PCT and 1 type II PCT. HFE polymorphism: 2 cases with C282Y/H63D; H63D polymorphism in 8. PCT manifestations resolved with PCT treatment in 4 patients, almost completely in 7 patients, 1 patient referred stabilization and one worsened. After DAA treatment all the residual lesions resolved, what always led to specific treatment interruption. Conclusions: Our series of cases of HCV-associated PCT shows that SVR after DAA treatment leads to PCT resolution. Porphyrin levels are not needed after ending PCT specific treatment interruption when there are no residual skin lesions in HCV-associated PCT.
MeSH term(s)	Antiviral Agents/therapeutic use ; Female ; Hepatitis C/complications ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Humans ; Middle Aged ; Mutation ; Porphyria Cutanea Tarda/complications ; Porphyria Cutanea Tarda/etiology ; Sustained Virologic Response
Chemical Substances	Antiviral Agents
Language	Spanish
Publishing date	2021-09-22
Publishing country	Spain
Document type	Journal Article ; Observational Study
ZDB-ID	632502-6
ISSN	0210-5705
ISSN	0210-5705
DOI	10.1016/j.gastrohep.2021.09.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2044: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Interacciones farmacocinéticas.

Arazo Garcés, Piedad / de los Santos Gil, Ignacio

Enfermedades infecciosas y microbiologia clinica

2013 Volume 31 Suppl 2, Page(s) 12–19

Abstract: Rilpivirine (RPV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has been approved for use in treatment-naïve patients and which has potent antiviral activity. Its adverse effects profile differs from that of first-generation NNRTs. The ... ...

Title translation	Pharmacokinetic interactions.
Abstract	Rilpivirine (RPV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has been approved for use in treatment-naïve patients and which has potent antiviral activity. Its adverse effects profile differs from that of first-generation NNRTs. The pharmacological interactions produced by RPV are due to its effects on the CYP450 system; RPV is a substrate and mild inducer of CYP3A4. Moreover, in vitro, RPV inhibits glycoprotein-P. RPV has clinically significant pharmacological interactions, especially with protease inhibitors (except boosted darunavir and lopinavir) and the NNRTIs efavirenz and nevirapine. Coadministration of RPV with drugs that increase gastric pH, such as omeprazole, or those inducing CYP3A4, such as rifampicin, can significantly reduce RPV concentrations and is contraindicated. The concomitant use of RPV with a CYP3A4 inhibitor (such as clarithromycin) can increase RPV concentrations. Administration of PRV with food is recommended to obtain better absorption and adequate plasma values.
MeSH term(s)	Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/blood ; Anti-HIV Agents/pharmacokinetics ; Anti-HIV Agents/therapeutic use ; Anti-Infective Agents/pharmacokinetics ; Anticonvulsants/pharmacokinetics ; Contraceptives, Oral/pharmacokinetics ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inducers/pharmacokinetics ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Drug Interactions ; Food-Drug Interactions ; Gastrointestinal Agents/pharmacokinetics ; HIV Infections/drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics ; Intestinal Absorption ; Nitriles/administration & dosage ; Nitriles/blood ; Nitriles/pharmacokinetics ; Nitriles/therapeutic use ; Proton Pump Inhibitors/pharmacokinetics ; Pyrimidines/administration & dosage ; Pyrimidines/blood ; Pyrimidines/pharmacokinetics ; Pyrimidines/therapeutic use ; Reverse Transcriptase Inhibitors/administration & dosage ; Reverse Transcriptase Inhibitors/blood ; Reverse Transcriptase Inhibitors/pharmacokinetics ; Reverse Transcriptase Inhibitors/therapeutic use ; Rilpivirine
Chemical Substances	Anti-HIV Agents ; Anti-Infective Agents ; Anticonvulsants ; Contraceptives, Oral ; Cytochrome P-450 CYP3A Inducers ; Cytochrome P-450 CYP3A Inhibitors ; Gastrointestinal Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Nitriles ; Proton Pump Inhibitors ; Pyrimidines ; Reverse Transcriptase Inhibitors ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; CYP3A4 protein, human (EC 1.14.14.55) ; Rilpivirine (FI96A8X663)
Language	Spanish
Publishing date	2013-11-19
Publishing country	Spain
Document type	Journal Article ; Review
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/S0213-005X(13)70138-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Ambulatory Blood Pressure Monitoring in HIV-Infected Patients: Usefulness for Cardiovascular Risk Assessment.

Gómez-Berrocal, Ana / De Los Santos-Gil, Ignacio / Abad-Pérez, Daniel / Gutiérrez-Liarte, Ángela / Ibáñez-Sanz, Patricia / Sanz-Sanz, Jesús / Suárez, Carmen

Journal of the International Association of Providers of AIDS Care

2020 Volume 19, Page(s) 2325958220935693

Abstract: Background: There is a lack of consensus regarding the risk of hypertension in HIV-infected patients compared to the general population. Ambulatory blood pressure monitoring (ABPM) is the most accurate method for the hypertension diagnosis. Nevertheless, ...

Abstract	Background: There is a lack of consensus regarding the risk of hypertension in HIV-infected patients compared to the general population. Ambulatory blood pressure monitoring (ABPM) is the most accurate method for the hypertension diagnosis. Nevertheless, it is rarely used in HIV clinical care. Materials and methods: All HIV-infected patients who underwent 24 hours ABPM were included. The agreement between office blood pressure (BP) readings and ABPM was analyzed. The rate of patients with masked hypertension (MH), isolated clinical hypertension, and nocturnal hypertension was obtained. Furthermore, it was analyzed if the differences between both methods may affect the cardiovascular risk (CVR) assessment. Results: A total of 116 patients were included. The κ coefficient between office BP and ABPM was 0.248. Over a quarter of the cohort was diagnosed with MH-25.8% (CI 95% 17.7%-34.0%), and 12% (CI 95%: 6.1%-16.1%) was diagnosed with ICH. Moreover, 19% of patients had hypertension exclusively during the night. The patients classified as low risk according to the CVR scores had a different diagnosis with ABPM than with office BP ( Conclusions: The agreement between office BP and ABPM was low in HIV-infected patients. Ambulatory BP monitoring is useful in HIV-infected patients as a hypertension diagnosis method, especially among patients classified as low risk.
MeSH term(s)	Adult ; Aged ; Blood Pressure Monitoring, Ambulatory ; Cardiovascular Diseases/diagnosis ; Cohort Studies ; Female ; HIV Infections/complications ; HIV Infections/diagnosis ; Heart Disease Risk Factors ; Homosexuality, Male ; Humans ; Hypertension/diagnosis ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Risk Factors
Language	English
Publishing date	2020-08-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2709037-1
ISSN	2325-9582 ; 2325-9574
ISSN (online)	2325-9582
ISSN	2325-9574
DOI	10.1177/2325958220935693
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Tratamiento de la toxicidad renal en el paciente positivo al virus de la inmunodeficiencia humana. Qué medir, cómo medirlo y con qué frecuencia.

Barril Cuadrado, Guillermina / de Los Santos Gil, Ignacio

Enfermedades infecciosas y microbiologia clinica

2009 Volume 26 Suppl 8, Page(s) 55–61

Abstract: Chronic kidney disease in patients with HIV is being recognized as one of the most frequent comorbidities of this disease and consequently much research is currently being performed in this area. The possible manifestations are highly varied and ... ...

Title translation	Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently.
Abstract	Chronic kidney disease in patients with HIV is being recognized as one of the most frequent comorbidities of this disease and consequently much research is currently being performed in this area. The possible manifestations are highly varied and consequently a high index of suspicion is required. Appropriate investigations should be performed from the moment patients first seek care to rule out renal disease and to prevent worsening, with the diagnostic or therapeutic measures that may subsequently be required. One of the most common problems is nephrotoxicity caused by some drugs and cases associated with tenofovir are becoming more frequently described. However, there is wide clinical experience with this drug and renal toxicity associated with its use is uncommon both in clinical trials and in clinical practice. Familiarity with what may happen, the associated factors and appropriate patient management are essential.
MeSH term(s)	Adenine/adverse effects ; Adenine/analogs & derivatives ; Adenine/therapeutic use ; Algorithms ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; Clinical Trials as Topic/statistics & numerical data ; Cohort Studies ; Creatinine/blood ; Drug Monitoring ; Female ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans ; Hypophosphatemia/chemically induced ; Hypophosphatemia/diagnosis ; Incidence ; Kidney Diseases/chemically induced ; Kidney Diseases/complications ; Kidney Diseases/diagnosis ; Kidney Diseases/epidemiology ; Kidney Diseases/metabolism ; Kidney Function Tests ; Kidney Tubules/physiopathology ; Male ; Organophosphonates/adverse effects ; Organophosphonates/therapeutic use ; Proteinuria/chemically induced ; Proteinuria/etiology ; Reverse Transcriptase Inhibitors/adverse effects ; Reverse Transcriptase Inhibitors/therapeutic use ; Tenofovir ; Time Factors ; beta 2-Microglobulin/urine
Chemical Substances	Anti-HIV Agents ; Organophosphonates ; Reverse Transcriptase Inhibitors ; beta 2-Microglobulin ; Tenofovir (99YXE507IL) ; Creatinine (AYI8EX34EU) ; Adenine (JAC85A2161)
Language	Spanish
Publishing date	2009-01-01
Publishing country	Spain
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1157/13126272
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.

Corma-Gómez, Anaïs / Macías, Juan / Merino Muñoz, Dolores / Téllez, Francisco / Granados, Rafael / Morano, Luis E / De Los Santos Gil, Ignacio / Vera-Méndez, Francisco J / Collado, Antonio / Palacios, Rosario / Pineda, Juan A

The Journal of infection

2019 Volume 79, Issue 1, Page(s) 30–35

Abstract: Objectives: To compare the efficacy of sofosbuvir/ledipasvir (SOF/LDV) for 8 weeks (SL8) versus a 12-week course of SOF/LDV (SL12) among HIV/HCV-coinfected patients in clinical practice. In addition we compared sustained virological response (SVR) rates ...

Abstract	Objectives: To compare the efficacy of sofosbuvir/ledipasvir (SOF/LDV) for 8 weeks (SL8) versus a 12-week course of SOF/LDV (SL12) among HIV/HCV-coinfected patients in clinical practice. In addition we compared sustained virological response (SVR) rates achieved with SL8 in HCV-monoinfected and HIV/HCV-coinfected patients in a real life setting. Methods: HCV-infected patients were retrospectively selected from the HEPAVIR-DAA and GEHEP-MONO real-life prospective cohorts if they fulfilled the following criteria: 1) Infected with genotype 1; 2) Treatment with SL8 or SL12; 3) Treatment naïve prior to receiving SL8 or SL12; 4) Absence of cirrhosis; 5) Baseline HCV RNA<6 × 10 Results: In the SL8 group, 107 (51%) HCV-monoinfected and 102 (49%) HIV/HCV-coinfected patients were included. One hundred and sixty-four (43%) HCV-monoinfected subjects and 220 (57%) HIV/HCV-coinfected patients received SL12. SVR12 rates for HIV/HCV-coinfected patients treated with SL8 vs SL12 were SVR12 92.2% vs. 97.3% (p = 0.044) and the respective relapse rates were 4.9% vs. 0.5% (p = 0.013). SVR12 rates for SL8 among HCV-monoinfected and HIV/HCV-coinfected patients were: 96.3% vs. 92.2% (p = 0.243), respectively. The corresponding relapse rates were 0.9% vs. 4.9% (p = 0.112). Conclusion: HIV/HCV-coinfected patients reach high rates of SVR12 with SL8, although lower than with SL12, mainly due to a higher probability of relapse. SVR12 rates with SL8 are numerically lower and the proportion of relapses higher in HIV/HCVcoinfected patients than in HCV-monoinfected subjects.
MeSH term(s)	Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Coinfection/drug therapy ; Female ; Fluorenes/therapeutic use ; HIV Infections/complications ; Hepatitis C, Chronic/drug therapy ; Humans ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Sofosbuvir/therapeutic use ; Sustained Virologic Response ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Benzimidazoles ; Fluorenes ; ledipasvir (013TE6E4WV) ; Sofosbuvir (WJ6CA3ZU8B)
Language	English
Publishing date	2019-05-14
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	424417-5
ISSN	1532-2742 ; 0163-4453
ISSN (online)	1532-2742
ISSN	0163-4453
DOI	10.1016/j.jinf.2019.05.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1501: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 48: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.

Perez Elias, Maria Jesus / Alejos, Belen / Gutierrez, Maria Mar / Crespo, Manuel / De Los Santos Gil, Ignacio / Ribera, Esteve / Galindo, Maria Jose / Lozano, Fernando / Payeras Cifre, Antonio / Boix, Vicente / Montero-Alonso, Marta / Sanz, José / De La Torre Lima, Javier / Palacios, Rosario / De La Fuente Moral, Sara / Martinez, Esteban

The Journal of antimicrobial chemotherapy

2021 Volume 76, Issue 4, Page(s) 1046–1050

Abstract: Background: Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been ... ...

Abstract	Background: Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been observed in clinical trials. Data regarding the impact of combination of those drugs on Cr-eGFR, in the clinical practice, are scarcely known. Methods: Changes in Cr-eGFR after starting darunavir/cobicistat alone or in combination with dolutegravir and/or rilpivirine were studied in a nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat. The relationship between Cr-eGFR changes over time and the use of darunavir/cobicistat alone or darunavir/cobicistat plus dolutegravir and/or rilpivirine adjusted by different HIV patient's characteristics, socio-demographics, HIV severity and use of tenofovir concomitant medication other than antiretrovirals was explored through univariate and multivariate analyses. Results: The analysis included 725 patients. At 48 weeks, the combination of two or more IPTCrS (darunavir/cobicistat with rilpivirine and/or dolutegravir) was associated with higher decreases in Cr-eGFR [adjusted median difference (±SD) -3.5 ± 1.6 (95% CI -6.6 to -0.3), P = 0.047], and a decrease up to or higher than 15 mL/min/1.73 m2 was more frequent [adjusted OR 3.233 (95% CI 1.343-7.782), P = 0.009], with respect to darunavir/cobicistat alone. The Cr-eGFR changes between darunavir/cobicistat and darunavir/cobicistat with rilpivirine and/or dolutegravir showed more significant decreases in patients taking two or more IPTCrS at 12, 24 and 48 weeks. (ClinicalTrials.gov: NCT03042390). Conclusions: Concomitant use of darunavir/cobicistat plus IPTCrS dolutegravir, rilpivirine, or both produced an additive effect in the expected Cr-eGFR decrease.
MeSH term(s)	Anti-HIV Agents/therapeutic use ; Cobicistat/therapeutic use ; Creatinine ; Darunavir/therapeutic use ; Glomerular Filtration Rate ; HIV Infections/drug therapy ; Humans ; Retrospective Studies
Chemical Substances	Anti-HIV Agents ; Creatinine (AYI8EX34EU) ; Cobicistat (LW2E03M5PG) ; Darunavir (YO603Y8113)
Language	English
Publishing date	2021-02-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkaa547
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hipoacusia neurosensorial de etiología sifilítica en un paciente con infección por virus de la inmunodeficiencia humana.

Valencia-La Rosa, Jorge Antonio / Gómez-Dávila, Christian / Sanz-Sanz, Jesús / de Los Santos-Gil, Ignacio

Enfermedades infecciosas y microbiologia clinica

2014 Volume 32, Issue 5, Page(s) 336–337

Title translation	Neurosensory loss hearing of syphilitic etiology in a patient with human immunodeficiency virus infection.
MeSH term(s)	Adult ; HIV Infections/complications ; Hearing Loss, Sensorineural/microbiology ; Humans ; Male ; Syphilis/complications
Language	Spanish
Publishing date	2014-05
Publishing country	Spain
Document type	Case Reports ; Letter
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2013.07.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalencia y características de los pacientes con infección por virus de la inmunodeficiencia humana (VIH) diagnosticados de novo en un servicio de urgencias.

Pizarro Portillo, Alberto / Del Arco Galán, Carmen / de Los Santos Gil, Ignacio / Rodríguez Salvanés, Francisco / Negro Rua, Mónica / Del Rey Ubago, Ana

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias

2016 Volume 28, Issue 5, Page(s) 313–319

Abstract: Objectives: To estimate the prevalence of undiagnosed human immunodeficiency virus (HIV) infection detected by routine testing of patients seeking care in an emergency department and to describe the characteristics associated with new HIV-infection ... ...

Title translation	Prevalence of undiagnosed human immunodeficiency virus infection in an emergency department and the characteristics of newly diagnosed patients.
Abstract	Objectives: To estimate the prevalence of undiagnosed human immunodeficiency virus (HIV) infection detected by routine testing of patients seeking care in an emergency department and to describe the characteristics associated with new HIV-infection diagnosis. Material and methods: Walk-in patients between the ages of 15 and 75 years who required a blood test were included. Routine fourth-generation enzyme-linked immunoassays were performed to detect HIV infection in all samples extracted. Patients with positive results were referred to the infectious diseases department for monitoring and treatment. Results: Blood samples for 1722 patients were analyzed. Twenty-one patients (1.2%) refused to allow their samples to be tested; 19 more samples (1.1%) could not be tested. The prevalence of undiagnosed HIV infection among the remaining 1682 remaining patients was 0.6% (95% CI, 0.23%-0.96%). The prevalence tended to be nonsignificantly higher among patients born outside Spain (0.97% [95% CI, 0.3%-2.20%]) and in 36-50-year-olds (1.46% [95% CI, 0.4%-2.5%]). Characteristics associated with undiagnosed HIV infection were male sex (odds ratio [OR], 5.78 [95% CI, 1.0-31.4]), presenting with a chief complaint that suggested infection (OR, 8.14 [95% CI, 1.6-41.4]), and a history of hepatitis (OR, 5.53 [95% CI, 1.1-27.7]). Conclusion: The prevalence of undiagnosed HIV infection in our emergency department was high at 0.6%. The rate of patient acceptance of routine HIV testing was high. Strategies that target improving the detection of undiagnosed HIV infection are advisable.
Language	Spanish
Publishing date	2016-10
Publishing country	Spain
Document type	English Abstract ; Journal Article
ZDB-ID	2127173-2
ISSN	2386-5857 ; 1137-6821
ISSN (online)	2386-5857
ISSN	1137-6821
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.

Neukam, Karin / Morano-Amado, Luis E / Rivero-Juárez, Antonio / Mancebo, María / Granados, Rafael / Téllez, Francisco / Collado, Antonio / Ríos, María J / de Los Santos-Gil, Ignacio / Reus-Bañuls, Sergio / Vera-Méndez, Francisco / Geijo-Martínez, Paloma / Montero-Alonso, Marta / Suárez-Santamaría, Marta / Pineda, Juan A

HIV clinical trials

2017 Volume 18, Issue 3, Page(s) 126–134

Abstract: Objective: HIV/HCV-coinfected patients and hepatitis C virus (HCV) monoinfected subjects are thought to respond equally to direct-acting antiviral (DAA)-based therapy despite the lack of data derived from clinical trials. This study is aimed to evaluate ...

Abstract	Objective: HIV/HCV-coinfected patients and hepatitis C virus (HCV) monoinfected subjects are thought to respond equally to direct-acting antiviral (DAA)-based therapy despite the lack of data derived from clinical trials. This study is aimed to evaluate the impact of HIV coinfection on the response to DAA-based treatment against HCV infection in the clinical practice. Patients and methods: In a prospective multicohort study, patients who initiated DAA-based therapy at the Infectious Disease Units of 33 hospitals throughout Spain were included. The primary efficacy outcome variables were the achievement of sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12). Results: A total of 908 individuals had reached the SVR12 evaluation time-point, 426 (46.9%) were HIV/HCV-coinfected, and 472 (52%) received interferon (IFN)-free therapy. In an intention-to-treat analysis, SVR12 rates in subjects with and without HIV-coinfection were 55.3% (94/170 patients) versus 67.3% (179/266 subjects; p = 0.012) for IFN-based treatment and 86.3% (221/256 subjects) versus 94.9% (205/216 patients, p = 0.002) for IFN-free regimens. Relapse after end-of-treatment response to IFN-free therapy was observed in 3/208 (1.4%) HCV-monoinfected subjects and 10/231 (4.4%) HIV/HCV-coinfected individuals (p = 0.075). In a multivariate analysis adjusted for age, sex, transmission route, body-mass index, HCV genotype, and cirrhosis, the absence of HIV-coinfection (adjusted odds ratio: 3.367; 95% confidence interval: 1.15-9.854; p = 0.027) was independently associated with SVR12 to IFN-free therapy. Conclusions: HIV-coinfection is associated with worse response to DAA-based therapy against HCV infection. In patients receiving IFN-free therapy, this fact seems to be mainly driven by a higher rate of relapses among HIV-coinfected subjects.
Language	English
Publishing date	2017-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2060516-X
ISSN	1945-5771 ; 1528-4336
ISSN (online)	1945-5771
ISSN	1528-4336
DOI	10.1080/15284336.2017.1330801
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5543: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicación de tratamiento en España. ¿Por qué no inician tratamiento quienes lo tienen indicado? Estudio Bridgap.

Viciana-Fernández, Pompeyo / Falcó, Vicenç / Castaño, Manuel / de los Santos-Gil, Ignacio / Olalla-Sierra, Julián / Hernando, Asunción / Deig, Elisabet / Clotet, Bonaventura / Knobel, Hernando / Podzamczer, Daniel / Pedrol, Pere Domingo

Enfermedades infecciosas y microbiologia clinica

2015 Volume 33, Issue 6, Page(s) 397–403

Abstract: Introduction: In Spain, HIV treatment guidelines are well known and generally followed. However, in some patients there are no plans to initiate ART despite having treatment indications. The current barriers to ART initiation are presented.: Methods: ...

Title translation	Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study.
Abstract	Introduction: In Spain, HIV treatment guidelines are well known and generally followed. However, in some patients there are no plans to initiate ART despite having treatment indications. The current barriers to ART initiation are presented. Methods: A cross-sectional survey including every HIV infected patient in care in 19 hospitals across Spain in 2012, with ≥1 indication to start ART according to 2011 national treatment guidelines, who had not been scheduled for ART initiation. Reasons for deferring treatment were categorized as follows (non-exclusive categories): a) The physician thinks the indication is not absolute and prefers to defer it; b) The patient does not want to start it; c) The physician thinks ART must be started, but there is some limitation to starting it, and d) The patient has undetectable viral load in absence of ART. Results: A total of 256 patients, out of 784 originally planned, were included. The large majority (84%) were male, median age 39 years, 57% MSM, 24% heterosexuals, and 16% IDUs. Median time since HIV diagnosis was 3 years, median CD4 count, 501 cells/mm3, median viral load 4.4 log copies/ml. Main ART indications were: CD4 count <500 cells/mm(3), 48%; having an uninfected sexual partner, 28%, and hepatitis C coinfection, 23%. Barriers due to, the physician, 55%; the patient, 28%; other limitations, 23%; and undetectable viral load, 6%. Conclusions: The majority of subjects with ART indication were on it. The most frequent barriers among those who did not receive it were physician-related, suggesting that the relevance of the conditions that indicate ART may need reinforcing.
MeSH term(s)	Adult ; Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/psychology ; Antiretroviral Therapy, Highly Active/utilization ; Attitude of Health Personnel ; Comorbidity ; Contraindications ; Cross-Sectional Studies ; Female ; Guideline Adherence ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Hepatitis, Viral, Human/epidemiology ; Humans ; Male ; Medication Adherence ; Middle Aged ; Practice Guidelines as Topic ; Practice Patterns, Physicians'/statistics & numerical data ; Sexual Behavior ; Spain ; Substance Abuse, Intravenous/epidemiology ; Treatment Refusal ; Viral Load
Language	Spanish
Publishing date	2015-06
Publishing country	Spain
Document type	Journal Article
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2014.06.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito